Liu Yifei, Nevins Justin C, Carruthers Kara M, Doucette William R, McDonough Randal P, Pan Xiaoyun
Program of Pharmaceutical Socioeconomics, University of Iowa, Iowa City 52242, USA.
J Am Pharm Assoc (2003). 2007 Jul-Aug;47(4):521-6. doi: 10.1331/JAPhA.2007.05107.
To describe the development, implementation, and financial aspects of a sustainable osteoporosis screening service in a community pharmacy and report osteoporosis risk factors for women screened during the 48 months in which the screening service was in operation.
An independent community pharmacy (Main at Locust Pharmacy Clinic) in Davenport, Iowa, beginning in 1999.
The osteoporosis screening service was provided by a staff pharmacist, a pharmacy resident, or a combination of a pharmacist and a resident. The service included use of the Hologic Sahara Bone Sonometer at the heel and education of the patient. Patient education consisted of a discussion of screening results, an overview of osteoporosis, and recommendations to address risk factors.
For patients who received osteoporosis screening, an overall cumulative risk score and a cumulative modifiable risk score were calculated. Patients were identified as having high (T-score <or=-1), moderate (-1 < T-score <0), or low (T-score >or=0) risk. An analysis was performed to determine the net financial gain or loss of osteoporosis screening.
Osteoporosis screening service.
T-score, overall cumulative risk score, cumulative modifiable risk score, and net financial gain of service.
A total of 444 women received the osteoporosis screening service during 48 months. More than 90% of the women had an overall cumulative risk score of at least 3, and 83.3% had at least one modifiable risk factor. According to the bone density tests, about 58% of the women were at high risk for osteoporosis and 25.7% were at moderate risk. The service had a net gain if provided by a pharmacist ($4,823.72), a resident ($8,153.72), or a combination of a pharmacist and a resident ($6,488.72).
This pharmacy-based osteoporosis screening service effectively identified patients at risk for osteoporosis and was sustainable for 48 months. Other community pharmacies are encouraged to offer similar services.
描述社区药房可持续骨质疏松症筛查服务的开展、实施及财务状况，并报告在筛查服务运行的48个月期间接受筛查的女性的骨质疏松症风险因素。
始于1999年，位于爱荷华州达文波特的一家独立社区药房（蝗虫街药房诊所主店）。
骨质疏松症筛查服务由一名药剂师、一名药房住院医师或药剂师与住院医师联合提供。该服务包括使用足跟部的Hologic Sahara骨超声仪以及对患者进行教育。患者教育包括对筛查结果的讨论、骨质疏松症概述以及针对风险因素的建议。
对于接受骨质疏松症筛查的患者，计算总体累积风险评分和累积可改变风险评分。将患者确定为高风险（T值≤ -1）、中度风险（-1 < T值 < 0）或低风险（T值≥ 0）。进行分析以确定骨质疏松症筛查的净财务收益或损失。
骨质疏松症筛查服务。
T值、总体累积风险评分、累积可改变风险评分以及服务的净财务收益。
在48个月期间，共有444名女性接受了骨质疏松症筛查服务。超过90%的女性总体累积风险评分至少为3，83.3%的女性至少有一个可改变风险因素。根据骨密度测试，约58%的女性有骨质疏松症高风险，25.7%的女性有中度风险。如果由药剂师提供该服务，净收益为4,823.72美元；由住院医师提供，净收益为8,153.72美元；由药剂师和住院医师联合提供，净收益为6,488.72美元。
这项基于药房的骨质疏松症筛查服务有效地识别了有骨质疏松症风险的患者，并且可持续运行48个月。鼓励其他社区药房提供类似服务。
